<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02082912</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00035176</org_study_id>
    <nct_id>NCT02082912</nct_id>
  </id_info>
  <brief_title>NMDA Receptors in Motor Learning in Humans</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to focus on enhancing upper limb recovery in patients
      post-stroke by using robotic-assisted therapy in combination with a drug to improve learning
      new motor skills.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disability after a stroke is common, leaving 65% of patients unable to use their affected
      hand in daily activities after 6 months. Frequently, these limitations can cause a decreased
      quality of life. Therefore, the purpose of this study is to understand the important factors
      in rehabilitation therapy that help improve arm function after stroke. This information may
      help to ultimately reduce disability and improve quality of life in patients with stroke.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Grip Strength of Affected Hand</measure>
    <time_frame>Baseline, 3 weeks (end of treatment)</time_frame>
    <description>Hand-grip strength was assessed using the whole hand and defined as the average of 3 trials using a calibrated Jamar dynamometer (Jamar Dynamometer, Asimow Engineering Co., Santa Monica, CA), with the elbow flexed to 90ยบ and the forearm in a neutral position. This is the standardized method for measuring hand-grip strength with a Jamar dynamometer recommended by the American Society of Hand Therapists. Change was calculated by subtracting baseline from outcome at week 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Stroke Impact Scale Score</measure>
    <time_frame>Baseline and at end of 3 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depressive Symptoms</measure>
    <time_frame>Baseline and at end of 3 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Memory and Information Processing Speed</measure>
    <time_frame>Baseline and at end of 3 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Motor Task Performance</measure>
    <time_frame>Baseline and at end of 3 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <description>D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks</description>
    <arm_group_label>D-cycloserine</arm_group_label>
    <other_name>Seromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill PO twice weekly (Monday and Wednesday) for three weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HandMentor Pro</intervention_name>
    <description>The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).</description>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between the ages of 18 and 95 years

          -  of either sex

          -  of diverse ethnic background

          -  have experienced a single unilateral hemispheric or brainstem stroke 3 or more months
             prior

          -  if have experienced more than one stroke, will be accepted only if all strokes are on
             the same side of the brain, there is no history of a clinical ischemic or hemorrhagic
             event affecting the other hemisphere, and there is no CT or MRI evidence of more than
             one a lacune or minor ischemic demylination affecting the other hemisphere.

          -  active motions of the wrist and hand: 10 of wrist extension from a relaxed flexed
             position; 10 of extension of any two digits at any joint, and 10 of thumb extension at
             either joint. All active motions must be repeated 3 times within one minute.

          -  passive range of motion: 90 of flexion and abduction and 45 external and internal
             rotation at the shoulder; 45 elbow supination and pronation; elbow extension limited
             by no more than 30; wrist extension to at least neutral; and digit extension limited
             by no more than 30.

          -  participants will not be required to exhibit any active shoulder or elbow motion

          -  ability to sit independently for at least 2 minutes

          -  Mini Mental Status Examination score greater than 24

          -  Motor Activity Log score less than 3

          -  Prospective participants who qualify but who have profound postural instability will
             undergo the intervention while walking with contact guarding or, when feasible, using
             their leg and more involved arm to propel a wheelchair.

          -  must have a score below 16 on the Center for Epidemiologic Studies Depression Scale

          -  must receive a score greater than 25 on the Folstein Mini Mental State Exam.

        Exclusion Criteria:

          -  any history of more than minor head trauma, subarachnoid hemorrhage, dementia or any
             other neurodegenerative disease, multiple sclerosis, HIV infection, drug or alcohol
             abuse, serious medical illness, schizophrenia, major refractory depression

          -  insufficient cardiopulmonary function to participate in low-intensity sustained upper
             extremity exercise

          -  severe visual impairment

          -  pregnancy

          -  breast feeding

          -  participation in intensive physical therapy within the prior 12 months

          -  inability to understand the potential risks and benefits of the study, personally
             provide informed consent, and understand and cooperate with treatment

          -  participating in other upper extremity rehabilitation, clinical or experimental,
             during the course of this trial.

          -  a score of less than 24 on the Folstein Mini-Mental State Exam

          -  a score of less than10 on the Boston Naming Test

          -  a first stroke less than 3 months or more than 48 months prior to the initiation of
             therapeutic intervention

          -  less than 18 years old

          -  clinical judgment of excessive frailty or lack of stamina

          -  serious uncontrolled medical conditions

          -  excessive pain in any joint of the more affected extremity that could limit ability to
             cooperate with the intervention

          -  passive range of motion less than 45 degrees for: abduction, flexion or external
             rotation at shoulder, or pronation of forearm

          -  greater than 30 degrees flexion contracture at any finger joint

          -  unable to stand independently for 2 min., transfer independently to and from the
             toilet or perform sit-to-stand

          -  current participation in other pharmacological or physical intervention studies, or
             have received injections of anti-spasticity drugs into upper extremity musculature
             within the past 3 months, or wish to have drugs injected in the foreseeable future

          -  receiving any anti-spasticity drugs orally at the time of expected participation

          -  received phenol injections less than 12 months prior to receiving therapy

          -  contemplating a move from proximity to the treatment site in less than 6 months from
             the randomization date.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Bulter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2014</study_first_posted>
  <results_first_submitted>April 9, 2015</results_first_submitted>
  <results_first_submitted_qc>April 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2015</results_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Andrew Butler, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 124 patients were screened from October 2008 to May 2010 at Emory University. Of those, 14 subjects qualified.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>D-cycloserine</title>
          <description>Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only subjects that completed the study were included in analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>D-cycloserine</title>
          <description>Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="7.3"/>
                    <measurement group_id="B2" value="53.7" spread="18.4"/>
                    <measurement group_id="B3" value="55.1" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Grip Strength of Affected Hand</title>
        <description>Hand-grip strength was assessed using the whole hand and defined as the average of 3 trials using a calibrated Jamar dynamometer (Jamar Dynamometer, Asimow Engineering Co., Santa Monica, CA), with the elbow flexed to 90ยบ and the forearm in a neutral position. This is the standardized method for measuring hand-grip strength with a Jamar dynamometer recommended by the American Society of Hand Therapists. Change was calculated by subtracting baseline from outcome at week 3.</description>
        <time_frame>Baseline, 3 weeks (end of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine</title>
            <description>Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Grip Strength of Affected Hand</title>
          <description>Hand-grip strength was assessed using the whole hand and defined as the average of 3 trials using a calibrated Jamar dynamometer (Jamar Dynamometer, Asimow Engineering Co., Santa Monica, CA), with the elbow flexed to 90ยบ and the forearm in a neutral position. This is the standardized method for measuring hand-grip strength with a Jamar dynamometer recommended by the American Society of Hand Therapists. Change was calculated by subtracting baseline from outcome at week 3.</description>
          <units>Newton</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" spread="3.56"/>
                    <measurement group_id="O2" value="8.44" spread="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stroke Impact Scale Score</title>
        <time_frame>Baseline and at end of 3 weeks of treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depressive Symptoms</title>
        <time_frame>Baseline and at end of 3 weeks of treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Memory and Information Processing Speed</title>
        <time_frame>Baseline and at end of 3 weeks of treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Motor Task Performance</title>
        <time_frame>Baseline and at end of 3 weeks of treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>D-cycloserine</title>
          <description>Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew John Butler</name_or_title>
      <organization>Emory University</organization>
      <phone>404-413-1415</phone>
      <email>ajbutle@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

